Hyperfine, Inc. (HYPR) vs Inovio Pharmaceuticals, Inc. (INO)
A side-by-side comparison of Hyperfine, Inc. and Inovio Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HYPR
Hyperfine, Inc.
$0.91HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
INO
Inovio Pharmaceuticals, Inc.
$1.14HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — HYPR vs INO
growth of $100 · dividends reinvested · last 6yHYPR -91.2% (-33.3%/yr)INO -98.9% (-53.2%/yr)HYPR compounded faster over this window
Log scale — wide-divergence pair
HYPR INO
HYPR vs INO: by the numbers
- •INO is the larger company ($79M vs $77M market cap).
- •Both run net losses; HYPR's is the smaller (-210.75% vs -130000.00% net margin).
Metrics side by side
Valuation
| Metric | HYPR | INO |
|---|---|---|
| P/S ratio | 4.64 | N/A |
| P/B ratio | 2.09 | 18.02 |
Profitability
| Metric | HYPR | INO |
|---|---|---|
| Gross margin | 51.41% | 100.00% |
| Operating margin | -273.43% | -132871.32% |
| Net margin | -210.75% | -130000.00% |
| ROE | -94.81% | -1542.57% |
| ROIC | -62.98% | -836.58% |
Growth (annualized)
| Metric | HYPR | INO |
|---|---|---|
| Revenue CAGR (5Y) | 77.73% | N/A |
| Total return CAGR (5Y) | -38.34% | -57.05% |
Frequently asked
- How have HYPR and INO total returns compared?
- Over the past 5 years, HYPR delivered -38.34% and INO delivered -57.05% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Hyperfine ROEInovio Pharmaceuticals ROEHyperfine operating marginInovio Pharmaceuticals operating marginHyperfine revenue growthInovio Pharmaceuticals revenue growthHyperfine free cash flowInovio Pharmaceuticals free cash flow
Hyperfine & Inovio Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.